Cure My Disease

Don't miss your cure!

 Log in / Sign up

New asthma combo shows promise in early trial

NCT ID NCT02296411

Completed Disease control Sponsor: Chiesi Farmaceutici S.p.A. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding a bronchodilator called glycopyrrolate bromide to a standard steroid inhaler (Qvar) helps people with uncontrolled asthma breathe better. 98 adults with asthma took either the combination or a placebo for 6 weeks, then switched. The main goal was to measure lung function over 12 hours. The results could point to a new treatment option for asthma that isn't fully controlled by steroids alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
glycopyrrolate bromide (an inhaled bronchodilator)
What this could lead to
If successful, this could lead to a new combination inhaler that helps people with asthma breathe better when their current medication isn't enough.
What could go wrong
This is a small, early-phase study (98 people) testing short-term effects only. The added drug may not work for everyone, and long-term safety or benefit is not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

Contacts and locations

Locations

  • Chiesi Clinical Trial Site 0101

    Sofia, 1000, Bulgaria

  • Chiesi Clinical Trial Site 0102

    Sofia, 1431, Bulgaria

  • Chiesi Clinical Trial Site 0103

    Sofia, 1431, Bulgaria

  • Chiesi Clinical Trial Site 0106

    Sevlievo, 5400, Bulgaria

  • Chiesi Clinical Trial Site 0107

    Rousse, 7002, Bulgaria

  • Chiesi Clinical Trial Site 0108

    Sofia, 1407, Bulgaria

  • Chiesi Clinical Trial Site 0109

    Sofia, 1336, Bulgaria

  • Chiesi Clinical Trial Site 0201

    Berlin, D-12165, Germany

  • Chiesi Clinical Trial Site 0202

    Leipzig, 04357, Germany

  • Chiesi Clinical Trial Site 0203

    Leipzig, 04207, Germany

  • Chiesi Clinical Trial Site 0206

    Magdeburg, 39112, Germany

  • Chiesi Clinical Trial Site 0207

    Radebeul, 01445, Germany

  • Chiesi Clinical Trial Site 0208

    Witten, 58452, Germany

  • Chiesi Clinical Trial Site 0301

    Pisa, 56124, Italy

  • Chiesi Clinical Trial Site 0303

    Pordenone, 33170, Italy

  • Chiesi Clinical Trial Site 0304

    Pisa, 56124, Italy

  • Chiesi Clinical Trial Site 0306

    Brescia, 25123, Italy

  • Chiesi Clinical Trial Site 0404

    Assen, 9401 RK, Netherlands

  • Chiesi Clinical Trial Site 0405

    Helmond, 5707 HA, Netherlands

  • Chiesi Clinical Trial Site 0501

    Bialystok, 15-010, Poland

  • Chiesi Clinical Trial Site 0502

    Bialystok, 15-351, Poland

  • Chiesi Clinical Trial Site 0503

    Elblag, 82-300, Poland

  • Chiesi Clinical Trial Site 0504

    Krakow, 31-011, Poland

  • Chiesi Clinical Trial Site 0505

    Wroclaw, 53-310, Poland

  • Chiesi Clinical Trial Site 0506

    Zgierz, 95-100, Poland

  • Chiesi Clinical Trial Site 0507

    Krakow, 30-349, Poland

  • Chiesi Clinical Trial Site 0510

    Lodz, 90-252, Poland

  • Chiesi Clinical Trial Site 0512

    Lodz, 90-141, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.